Diindolylmethane Bioavailability via CYP450 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acne and rosacea often fail to effectively address the underlying metabolic and bioavailability issues of diindolylmethane (DIM), leading to suboptimal therapeutic outcomes.
Innovation Solution
A pharmaceutical composition comprising a modulator of CYP450 enzymes, such as quercetin, combined with diindolylmethane and retinoic acid, to enhance the bioavailability and efficacy of DIM by reducing its metabolism and increasing its plasma concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If diindolylmethane is administered alone, then it is metabolized rapidly by CYP450 enzymes, but this leads to low bioavailability and suboptimal therapeutic outcomes
Solution Approach 1:
The patent introduces CYP450 modulators (such as quercetin, resveratrol, or curcumin) as intermediary substances that mediate between the administered diindolylmethane and the CYP450 enzymes. These modulators inhibit or induce the enzymes to control the metabolism rate of DIM, thereby regulating its bioavailability and plasma concentration to achieve optimal therapeutic outcomes.
2Reliability
If the dosage of diindolylmethane is increased to improve therapeutic effect, then plasma concentrations may increase, but metabolism by CYP450 enzymes also increases leading to reduced efficacy
Solution Approach 1:
The patent changes the pharmacokinetic parameters of diindolylmethane by co-administering CYP450 modulators. These modulators alter the metabolism rate parameter, half-life parameter, and plasma concentration parameter of DIM, allowing for optimized dosing regimens that maintain effective plasma levels while reducing excessive metabolism and loss of the active substance.
3Productivity
If CYP450 enzyme activity is high, then metabolism of various compounds is efficient, but this leads to rapid breakdown of diindolylmethane and reduced treatment efficacy
Solution Approach 1:
The patent applies preliminary anti-action by administering CYP450 modulators before or with diindolylmethane to pre-inhibit or pre-induce the enzyme activity. This preliminary modulation prevents the rapid metabolism that would otherwise occur, thereby protecting the therapeutic efficacy of DIM while still allowing controlled metabolic processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy significantly increases the bioavailability and plasma concentrations of diindolylmethane, leading to improved treatment outcomes for acne and rosacea by synergistically inducing CYP enzymes and altering pharmacokinetic parameters like Cmax and AUC.
Implementation Method 1
a first component comprising a modulator of a CYP450 enzyme... the CYP450 enzyme comprises CYP1A1, CYP1A2, CYP2D6, CYP2C8, CYP2C9, CYP3A4, CYP2C19, CYP19A1, or combinations thereof
Implementation Method 2
a second component comprising a substituted or unsubstituted diindolylmethane... a third component comprising a substituted or unsubstituted retinoic acid based compound
Data Source
AI summary
Described herein are pharmaceutical compositions comprising one or more modulators of a cytochrome 450 enzyme (CYP450) and substituted or unsubstituted diindolylmethane. Also described herein are methods for treating one or more skin conditions by administering a combination therapy comprising substituted or unsubstituted diindolylmethane and one or more modulators of CYP450. In particular, methods are disclosed for improving bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following the combination therapy.